





























Link to publication record in King's Research Portal
Citation for published version (APA):
Fornaro, M., Solmi, M., Stubbs, B., Veronese, N., Monaco, F., Novello, S., ... Vieta, E. (2020). Prevalence and
correlates of major depressive disorder, bipolar disorder and schizophrenia among nursing home residents
without dementia: systematic review and meta-analysis. The British journal of psychiatry : the journal of mental
science, 216(1), 6-15. https://doi.org/10.1192/bjp.2019.5
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
1 
 
Prevalence and Correlates of Severe Mental Illness Among Nursing Home 
Residents Without Dementia: Systematic Review and Meta-analysis 
 
Running title: “MDD in nursing homes” 
 
 
Michele Fornaro, MD, PhD 
 
Marco Solmi, MD, PhD 
 
Brendon Stubbs, PhD, MSc, BSc 
 
Nicola Veronese, MD, PhD 
 
Francesco Monaco, MD 
 
Stefano Novello, MD 
 
Andrea Fusco, MD 
 
Annalisa Anastasia, MD 
 
Domenico De Berardis, MD, PhD 
 
André F. Carvalho, MD, PhD 
 
Andrea de Bartolomeis, MD, PhD 
 
























Background: The elderly population and number of nursing homes residents are growing at a 
rapid pace globally. Uncertainty exists regarding the actual rates of corresponding severe mental 
illness (SMI) cases since previous evidence documenting high rates relies on sub-optimal 
methodology. Aims: To carry a systematic review and meta-analysis on the prevalence and 
correlates of SMI including major depressive disorder (MDD), bipolar disorder (BD) and 
schizophrenia-spectrum diseases (SSDs) among nursing homes residents without dementia. 
Method: Major electronic databases were systematically searched from 1980 up until July 2017 
for original studies reporting on the prevalence and correlates of MDD among nursing homes 
residents without dementia. The prevalence of MDD in this population was meta-analyzed 
through random-effects modeling, while potential sources of heterogeneity were examined 
through subgroup/meta-regression analyses. Results: Across 32 observational studies 
encompassing 13,394 nursing homes residents, 2110 cases were diagnosed as MDD, resulting in 
a pooled prevalence rate of 18.9% (95% C.I.=14.8%-23.8%). Heterogeneity was high (I2=97%, 
p=<.001); no evidence of publication bias was observed. Sensitivity analysis indicated the highest 
rates of MDD among North American residents (25.4%, 95% C.I.=18%-34.5%, p=<.001). 
Prevalence of either BD or SSDs could not be reliably pooled due to the paucity of corresponding 
data. Limitations: The paucity of quantitative data precluded further stratification of MDD 
features. Methodological quality of the included studies varied, hampering the overall 
generalizability of the results. Conclusions: MDD is highly prevalent among nursing homes 
residents without dementia. Efforts toward the prevention, early recognition, and management of 
MDD in this population are warranted. 
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The elderly population is increasing both in absolute numbers as well as in the 
percentage of the total population worldwide (1), with no exception for those with 
severe mental illness (SMI), including bipolar disorder (BD), major depressive disorder 
(MDD), schizoaffective disorder (SCZA) or schizophrenia (2). Whilst there is 
premature mortality among people with SMI, some individuals with SMI reach an 
advanced age and may experience considerable physical health burdens and multi-
morbidity; therefore, they may be more likely to need admission to a nursing home 
environment (3, 4). 
MDD is one of the most common mental disorders worldwide and is prevalent 
throughout the lifespan, with prevalence estimates of 1-5% in those 65 years of age and 
older (5). 
Regrettably, little is known about the actual rates and clinical features associated with 
MDD among nursing home residents, essentially due to the almost invariable systematic 
exclusion of elderly patients from selection into studies and the subsequent publication 
bias. 
In addition, nursing home residents with MDD may be either patients with 
disorder onset early in life (then lasting or recurring at an old age) or patients whose 
onset first occurs in late life, representing differential clinical and neurobiological 
phenotypes of depression (6-8). 
MDD deserves further accurate clinical epidemiological assessment focusing on 
those cases not related to or overlapping with dementias, ideally providing clear-cut 
prevalence estimates of MDD among nursing homes, which are most likely populated 
with elderly people. Patient-tailored treatment and prevention of depression in the 
elderly population should promote cognitive health, enhancing the chances of 
independent living and overall quality of life. 
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To the best of our knowledge, the only systematic review on the prevalence of 
psychiatric disorders among nursing home residents dates back to the year 2010, failed 
to use any quantitative pooling whatsoever, and documented long-term point prevalence 
rates of an MDD diagnosis up to 10% for nursing home residents and 29% for 
depressive symptoms overall (9). However, it must be remarked that this report merged 
a variety of different clinical phenotypes of depression, including BD cases and those 
“confounded” by comorbid dementia(s), lifetime substance abuse and/or anxiety 
disorders, just to name few. The study also limitied the search strategy to only the 
EMBASE dataset (9) and failed to adopt any reliable (semi-)structured interview based 
on any major standard diagnostic coding. 
Therefore, after stating the poor reliability of the previous reports on the matter, 
considerable uncertainty still surrounds the actual prevalence rates and clinical 
correlates associated with SMIs among nursing home residents. 
We, therefore, aimed to conduct a systematic review and meta-analysis of the 
prevalence and clinical correlates of SMIs focusing on MDD among nursing home 
residents without dementia, to have the diagnoses assessed by structured interviews based 
on either the Diagnostic and Statistical Manual for Mental Disorders (DSM) or the 
International Classification of Diseases (ICD), and to strive to control or avoid as many 






Search strategy and study selection 
The present systematic review adhered to the PRISMA (10) and the MOOSE guidelines 
(11). The international prospective register of systematic reviews (PROSPERO) 
(https://www.crd.york.ac.uk/PROSPERO/) registration number is CRD42018088312. 
Six authors divided into two teams (MF, AF, SN, AA and MS and FM) and independently 
searched PubMed, PsycINFO, and EMBASE databases for records indexed from the year 
1980 onwards (last updated, June 2017). The string was searched in PubMed and was 
adapted across varying datasets: ((nursing home*[Title/Abstract] OR long-term 
care[Title/Abstract] OR homes for the aged[Title/Abstract])) AND (((((((("Psychotic 
Disorders"[Mesh] OR "Bipolar Disorder"[Mesh]) OR "Depressive Disorder, 
Major"[Mesh]) OR ("Mood Disorders"[Mesh] OR "Seasonal Affective Disorder"[Mesh] 
OR "Affective Disorders, Psychotic"[Mesh])) OR ("Depression"[Mesh] OR "Depressive 
Disorder"[Mesh])) OR "Schizophrenia"[Mesh]) OR "Schizophrenia Spectrum and Other 
Psychotic Disorders"[Mesh])) OR (psychosis)). Additional details for the search strategy 
across varying datasets have been provided in supplementary material n.1. Finally, the 
results were augmented by a manual search and cross-references as depicted in figure n.1 
(study flow chart). 
Studies were deemed eligible if they were original peer-reviewed articles (any language), 
but not case report/series (i.e., with a sample size<10), that reported the prevalence of 
either MDD, BD, or schizophrenia/schizoaffective disorder among nursing home 
residents, or contained data allowing us to compute the prevalence. Late-onset cases of 
BD were those patients aged 60 years or older (12), and this age threshold was likewise 
applied to MDD and schizophrenia cases as well. Either naturalistic studies or 
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interventional studies with baseline prevalence data were included. Diagnosis of MDD, 
BD, or schizophrenia had to be made according to any version of the DSM or ICD. 
Data Extraction 
Six authors divided into two teams (MF, AF, SN, AA and MS and FM) and independently 
extracted data using a predetermined extraction form, and including the following: MDD, 
BD, or schizophrenia prevalence (or variables needed to compute it), author, year of 
publication, year of data collection, country/continent of data collection, study design, 
demographic characteristics, underlying main condition, employed clinical rating scales 
and the diagnostic criteria were used in conjunction with a validated structured interview, 
and essential clinical and pharmacological moderators, including but not limited to, 
prescription of first (FGAs) or second-generation (SGAs) atypical antipsychotics as well 
as the percentage of major medical comorbidities. Any eventual within- and between-
team disagreements were solved by the corresponding team principal investigator (MF 
for team n.1, and MS for team n.2), while between-team resolution was performed by a 
senior author (AFC) as necessary. 
Quality assessment 
We assessed the quality of the included studies using the Quality Assessment Tool for 
Observational Cohort and Cross-Sectional Studies (https://www.nhlbi.nih.gov/health-
pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort). 
The quality of the interventional studies was assessed using the Cochrane Risk of Bias 
Assessment Tool (13). 
For both rating tools, higher scores indicated poorer quality of the study. 




Due to the anticipated heterogeneity, we utilized a random-effects meta-analysis and 
computed the pooled prevalence and 95% confidence intervals (C.I.s) with 
Comprehensive Meta-Analysis (CMA, version 2) (14). Heterogeneity was assessed with 
the Cochrane Q and I2 statistics for each analysis (15). We conducted mixed-effect model 
meta-regression analyses with CMA, for outcomes with high heterogeneity (I2>50% 
and/or p=≤.05) and reported by ≥4 studies, to investigate potential moderators of the 
observed prevalence of SMI in nursing homes. We conducted sensitivity analyses 
according to country, continent, criteria used to define a given SMI, period of data 
collection (in decades), specific psychiatric diagnosis (MD, BD, and schizophrenia), and 
the quality of the study (post hoc assessment of good, fair, or poor quality) based on either 
the NIH or the Cochrane tools mentioned earlier, and using quartiles, we then merged the 
studies into two main categories to allow sensitivity prevalence analysis across the two 
main categories (as depicted in table n.1 and its footnotes).  
Depending on the available data, we aimed to investigate the following moderators: 
sample size, year of data collection, mean age, percentage of males, ethnicity, country, 
diagnostic criteria (DSM/ICD), major medical or psychiatric comorbidities whenever 
available, and quality of the study according to the NIH rating. 
Publication bias was assessed via visual inspection of funnel plots and with the Begg-
Mazumdar Kendall's tau (16) and Egger bias tests (17). In cases where publication bias 
was identified, we computed the trim and fill adjusted analysis (18) to remove the most 
extreme small studies from the positive side of the funnel plot, and re-computed the effect 





Out of the initial title and abstract assessment of 4776 hits after duplicate removal, we 
excluded 3882 papers, thus 894 full-text were further assessed (please refer to figure n.1 
for details). A total of 36 studies (19-53) could be included in the qualitative synthesis 
corresponding to a grand total sample size of 13,754 of nursing home residents included 
for qualitative analysis. Among the 36 studies, three (42, 43, 53) were assessed using the 
Cochrane quality evaluation tool since they were interventional studies: two of which 
were randomized clinical trials (RCTs) (42, 53) and one was a non-controlled prospective 
trial (43). Finally, 32 studies reported on MDD cases (19, 21-40, 42, 44-53), 3 studies 
reported on schizophrenia (20, 43, 54) (one schizophrenia study also documented a subset 
of BD cases (54)), and one study provided stratified results both on MDD and BD samples 
(37). We could not locate any study reporting on SCZA cases. 
Overall, 32 studies reporting on MDD samples (31 studies reporting just on MDD cases 
and 1 documenting BD cases as well) were included in the meta-analysis (19, 21-40, 42, 
44-54). 
Please refer to table n.1 for additional details, including the clinical features documented 
among nursing home residents with SMI. 
Meta-analysis of major depressive disorder prevalence, publication bias, heterogeneity 
and categorical subgroup comparisons 
The overall pooled MDD prevalence across 32 samples and 2110 MDD cases out of 
13,394 nursing home residents pooled for quantitative analysis was 18.9% (95% 
C.I.=14.8%-23.8%); please refer to figure n.2 for details. Heterogeneity was high 
(I2=97%, p=<0.001). Publication bias seemed unlikely (please refer to figure n.3 for 
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visual inspection of the funnel plot) (Egger test intercept=.726, (p=ns); Begg and 
Mazumdar’s test, continuity-adjusted Tau=.00202, p=ns). 
Subgroup analysis of major depressive disorder in nursing home residents 
As detailed in table n.2, the prevalence rates of MDD among nursing home residents 
significantly varied across geographical regions, being highest (point-prevalence 
rates=25.4%, 95% C.I.=18%-34.5%, p=<.001) in North America and lowest in Oceania 
(5.7%, 95% C.I.=3.2%-10%, p=<.001), although publication bias for North American 
studies could not be excluded (p=.015). The total overall between-region difference 
(p=<.001) means that the estimated prevalence rates statistically significantly differed 
across varying sub-groups according to geographical region. 
Similarly, the prevalence estimates of MDD varied according the design of the study, 
being the highest for prospective, non-controlled studies (44.1%, 95% C.I.=33.3%-
94.7%, p=ns) and lowest for cross-sectional studies (17.2%, 95% C.I.=13.2%-22%, 
p=<.001). There was a total overall between-design difference (p=<.001). 
In addition, the prevalence of MDD was higher among Caucasian nursing home residents 
(35.2%, 95% C.I.=16.7%-59.7%, p=ns) vs. Black/African American counterparts 
(17.5%, 95% C.I.=11.2%-26.4%, p=<.001) and was lowest among Hispanics or Latinos 
(5.7%, 95% C.I.=3.2%-10%, p=<.001). There was a total overall between-race/ethnicity 
difference (p=<.001). 
A DSM-III diagnosis of MDD was documented among 12.4% of the residents (95% 
C.I.=8.2%-18.2%, p=<.001), and a DSM-IV diagnosis of MDD was documented among 
21.3% of the residents (95% C.I.=15.2%-29.2%, p=<.001). A diagnosis of MDD made 
according to the ICD-9 or the ICD-10 criteria was documented among 30.9% (95% 
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C.I.=13.3%-56.6%, p=ns) of the nursing homes. There was a total overall difference 
based on diagnostic criteria (p=<.001). 
Concerning major psychiatric or other medical comorbidities, diabetes was recorded 
among 18.3% of the residents (95% C.I.=5.8%-44.9%, p=.023), anxiety comorbidity was 
seen among 43.1% of the residents (95% C.I.=10.8%-82.7%, p=ns), and cognitive 
impairment (yet not leading to dementia) was recorded among 18.5% of the residents 
(95% C.I.=6%-44.5%, p=.021). There was a total overall difference in psychiatric or other 
medical comorbidities (p=<.001). 
Finally, those observational studies appraised as moderate-to-poor quality according to 
the NIH tool mentioned earlier and the ad hoc created percentile recoding (please refer to 
the footnotes in table n.1) documented point-prevalence rates of MDD up to 17.1%, 
ranging between 12.1% to 23.4% (95% C.I., p=<.001). In contrast, those non-
interventional studies appraised as average-to-good quality documented point-prevalence 
rates of MDD at 18.3% (95% C.I.=12.5%-26%, p=<.001). There was a total overall 
difference between studies with varying quality (p=<.001). 
 
Mixed-effect meta-regression analysis of potential continuous variable moderators of 
major depressive disorder patients 
Supplementary materials n.2-5 provide a graphic synthesis of mean age at onset and 
mean age predictors respectively. Mixed-effect meta-regression analysis demonstrated 
that the publication year predicted higher rates of MDD among nursing home residents 
(β=.007, 95% C.I.=.001-.013, p=.019, k (number of studies)=32) and that age inversely 
predicted MDD prevalence (β=-.031, 95% C.I. .008-.046, p=<.001, k=22). Additionally, 
the higher the proportion of males among nursing home residents was, the higher the 
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overall rate of MDD was (β=.017, 95% C.I.=.010-.024, p=≤.001, k=25). As largely 
expected, the higher the antidepressant drug utilization was, the higher the overall rate 
of MDD diagnosis was (β=.006, 95% C.I.=.002-.015, p=.014, k=8). 
Variables unable to be included in the analyses 
We were unable to extract sufficient data to allow reliable pooling of the following 
clinical moderators: mean age at onset of MDD, current use of lithium, anti-consultant 
mood stabilizers, benzodiazepines, FGA or SGA drugs, current psychotropic 
polypharmacy (namely, two or more psychiatric drugs at once), obsessive-compulsive 
disorder, post-traumatic distress disorder, impulse-control disorder, suicidal behaviour, 
substance use (including abuse of over-the-counter pain-killer medications), tobacco 
use, and cardio-/cerebrovascular diseases (including obesity). In addition, we could not 
even run an exploratory meta-analysis of schizophrenia prevalence among nursing home 
residents due to the paucity of corresponding original studies (n=3) and the fact that 
these studies did not follow a naturalist approach. Similarly, BD nursing home residents 
could be appraised only for qualitative synthesis since the corresponding original 
studies were too few in number (n=2). 
 
Major biases found across the included studies reporting on major depressive disorder 
cases 
The following issues were documented in at least three studies: a relatively small 
sample size, a lack of clear-cut definition of the time frame the MDD symptoms were 
assessed, and/or a lack of an accurate description of the severity of the underlying 





This systematic review included 36 studies encompassing 13,754 individuals. Of these, it 
was possible to pool data from 13,394 individuals identifying 2110 MDD cases 
(documented by 32 original studies). In addition, we identified 192 schizophrenia cases 
described by 3 corresponding reports, but it was not possible to reliably pool data from 
these cases for quantitative synthesis due to non-naturalistic designs (the qualitative 
synthesis is nonetheless summarized in table 1). The mean prevalence of MDD across 
varying geographical regions was 18.9%. Mixed-model meta-regression analysis of the 
MDD subset revealed that the more recent the publication year was, the higher the 
reported prevalence of MDD among the nursing home residents; the older the mean age 
of the residents was, the lower the reported prevalence of MDD among the nursing home 
residents; the higher the proportion of males among the nursing home residents was, the 
higher the rates of MDD overall; and, as expected, the higher the antidepressant drug 
utilization, the higher were the rates of MDD overall. 
Finally, despite substantial heterogeneity, MDD prevalence was significantly affected by 
geographical region, study design, and ethnicity moderators. Nonetheless, concerning the 
study design, the only statistically significant rates of MDD were the ones related to cross-
sectional reports due to the paucity of prospective studies. 
Overall, the present report provides more accurate insights into the prevalence and clinical 
features associated with nursing home residents without dementia diagnosed with MDD 
than previous evidence (9). In fact, that published report provided only a qualitative 
synthesis of the evidence and failed to discriminate comorbid MDD cases with or without 
dementia, despite the intricate relationship that exists between depression and cognitive 
deficits, especially in the elderly (55). In addition, we retained only those studies relying 
on the structured interview(s) validated according to mainstream diagnostic codes rather 
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than merging overt MDD with depressive symptoms. Aiming at enhancing the quality of 
reporting, we purposely excluded those studies in which the diagnosis of MDD was not 
assessed by a structured interview. Nonetheless, we acknowledge that the use of 
structured interviews among nursing home residents may not be as popular as it is among 
the non-elderly adult population. Therefore, future primary studies should promote the 
use of standardized clinical ratings among the elderly SMI population. 
Strengths and limitations 
There are several limitations of the present study that should be acknowledged, allowing 
a critical interpretation of the results. 
The limitations include the high heterogeneity of the studies and populations, the 
relatively narrow range of the queried databases, as well as the assessment and diagnostic 
strategies for SMIs. This is with special reference to the lack of original studies involving 
BD samples and schizophrenia cases, and the total lack of studies providing clear-cut 
stratification of SSDs. 
Moreover, the studies assessing schizophrenia patients did not follow a naturalistic 
approach, in contrast to the ones documenting MDD (or BD) samples. This issue coupled 
with the paucity of corresponding primary studies following a naturalistic approach 
precluded meta-analytic assessment. In addition, due to the scarcity of corresponding 
data, we could not further stratify for earlier vs. later onset of MDD. Similarly, additional 
information is critically needed with respect to further potential confounding factors 
(namely, specific non-psychiatric medical comorbidities or accurate records of 
pharmacological resource utilization). 
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In this regard, it must be remarked that many elderly patients diagnosed with MDD are 
exposed to benzodiazepines, antipsychotics, and other tranquilizers, whereas 
antidepressant drugs could be under-utilized (56, 57). 
Nonetheless, people with highly disabling SMIs (namely, schizophrenia as well as BD), 
the onsets of which usually occur earlier in life than MDD onset and require exposure to 
higher/prolonged doses of drugs with significant cardiometabolic side effects, may have 
reduced life expectancy compared to their counterparts diagnosed with major depressive 
disorder (58, 59). This issue concurs with limited evidence on the matter. While one may 
assume that most severe SMIs would be admitted either to long-term psychiatric asylums 
or even to correctional institutes (as BD may lead to anti-social behaviour associated with 
higher use of the illicit substance) (60) rather than general medicine or multi-disciplinary 
nursing home facilities, the actual current practice suggests that there was a reduction in 
long-term institutional care places, with more patients, especially those that are 
functional, receiving treatment in the community rather than in care homes, which 
possibly contain more severely disabled patients. This perspective may explain the higher 
rates of MDD (and possibly other SMIs as well) over time (in line with the publication 
year trend). 
Clinical implications 
Taken together, the results from the present systematic review and meta-analysis lay the 
groundwork for replication studies to specifically address the above-raised issues 
considering that the actual prevalence of MDD among nursing home residents without 
dementia is high, which may also be the case for BD and schizophrenia, and where 
systematic assessment is particularly urged. There are several areas of research and need 
for stratification of nursing home residents with SMI that need to be addressed by future 
clinical research. For example, little is known about the rates of suicidal behaviour in such 
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populations, although the finding of lower rates of MDD among the older residents could 
be explained by increased mortality among the individuals who already committed 
suicide and/or had lower life expectancy due to severe medical morbidity. Similarly, 
nursing home residents who experience prolonged bed rest are at increased risk both for 
depression and for cardiometabolic issues, urging for patient-tailored physical therapy 
interventions as well. In addition, future clinical research on nursing home residents 
without dementia needs to systematically assess the cognitive and the treatment 
adherence profile of those individuals admitted to long-term facilities for the aged. 
Finally, given the high resource utilization, the socioeconomic burden and increasing life 
expectancy worldwide (despite the gap that still exists between people with SMI and the 
general elderly population), the present topic of research represents a crucial priority for 
practising clinicians, nursing personnel, and those involved in insurance plan making, as 
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Table 1: Qualitative synthesis of records. Included studies: n=36 (please note that the actual number of studies then included in the meta-analysis 
exceeded the present one since a couple of original records included multiple multi-diagnostic arms).  
Note: studies were sorted based on the year of publication. 
Overall, most of the studies were conducted in North America owing to the DSM criteria (either Third or Fourth Editions) and related to MDD 
samples. In most instance, females were overrepresented among the nursing homes residents without a current diagnosis of dementia (any type). 
Notably, major non-psychiatric medical comorbidities (e.g. diabetes, other cardio- or cerebrovascular conditions were rarely documented); 
similarly, prominent cognitive impairment (but not dementia) was relatively uncommon. 
 
Legend: DSM=Diagnostic and Statistical Manual for Mental Disorders; ICD=International Classification of Diseases; BD=Bipolar Disorder; 
MDD=Major Depressive Disorder; SCZ=Schizophrenia; SCZA=Schizoaffective Disorder; GAD=General Anxiety Disorder; RCT=Randomized 
Clinical Trial. 
 
Note: The quality of the 33 out 36 studies assessed using the NIH tool (https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-
risk-reduction/tools) has been further appraised by stratification into quartiles as depicted in the boxplot below, whereas score ranging 2-5 (1st and 
2nd quartiles merged) were regarded as moderate-poor quality (n=25/33 or 75% of the records) in contrast to higher scores (up to 7) regarded as fair-
good quality studies (3rd and 4th quartiles merged), n=9/33 or 24% of the records. Three interventional studies were appraised using the Cochrane 
tool (13) (two records scored as 7 were considered of fair quality vs. one record scoring 4 considered of poor quality). 
 
Note, 10 out of 36 studies were indexed after the year 2010 (roughly, 27% of the sample); studies indexed after the year 2010 may have nonetheless 
























Whole MDD sample 32 18.9% 14.8% 23.8% <.001 97% N - 
Geographical region 
Europe 10 16.5% 10.9% 24.1% <.001 97% N  
 
<.001 
North America 17 25.4% 18% 34.5% <.001 97% Y 
Oceania 1 5.7% 3.2% 10% <.001 0% - 
Other 4     89% Y 
Study design- 
Cross-sectional 28 17.2% 13.2% 22% <.001 97% Y  
<.001 
 
Prospective, open 2 44.1% 33.3% 94.7% Ns 98% Y 








Predominantly Black or 
African-American 
2 17.5% 11.2% 26.4% <.001 89% - 
 
Predominantly Hispanics 1 5.7% 3.2% 10% <.001 0% - 
Diagnostic criteria 
DSM-III 11 12.4% 8.2% 18.2% <.001 97% Y  
Ns 
 
DSM-IV 16 21.3% 15.2% 29.2% <.001 94% Y 
ICD-9 or ICD-10 5 30.9% 13.3% 56.6% Ns 99% Y 
Major psychiatric or another medical comorbidity 
Diabetes 3 18.3% 5.8% 44.9% .023 98% Y  
Ns Anxiety 4 43.1% 10.8% 82.7% ns 98% Y 
Cognitive impairment 
other than dementia 
3 18.5% 6% 44.5% .021 99% Y 
NIH quality appraisal 
Poor-moderate quality 14 17.1% 12.1% 23.4% <.001 95% Y  




Table 2. Random effect meta-analysis with sensitivity analyses of the prevalence of the major depressive disorder in homes. Note: publication bias 
could not be evaluated in case of three studies or fewer. 
  


















































Legend: MDD=Major depressive disorder; BD=Bipolar disorder; SCZA=schizoaffective disorder. 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097. 






























Additional records identified 
through other sources 
(Google scholar, n=0; textbooks, 
n=0) 




Records excluded  
(n=3882) 
1. Indexed before 1980 (n=123, 2.6%);  
2. Review/case report (n=341, 7.1%); 
3. Not related to research theme (n=4312, 
90.3%) 




Full-text articles excluded, with reasons, 
n=858 
(unable to retrieve, n=91; 
lack of either validated structured interview 
or diagnostic coding, n=482; 
lack of adequate diagnostic stratification 
and/or discrimination of dementias sub-
sample, n=116; not an original study, n=86; 
no clear-cut stratification of the results 
according to age, n=32; other reason(s), 
n=51). 
Additional information provided in table n.1. 
Studies included in qualitative synthesis 
(n=36), were 32 reporting on MDD cases, 1 study reporting on 
BD, 3 studies reporting on schizophrenia, and one study fetching 
stratified results both on MDD and BD samples. No study 
reporting on SCZA cases could be included. 
Studies included in Meta-analysis: n=32.  
 Figure 1 addendum: PRISMA 2009 checklist 
 




TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; 
results; limitations; conclusions and implications of key findings; systematic review registration 
number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
4 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
2 & 5 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale.  
5 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
5 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated.  
5 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta-analysis).  
5 
 Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data from investigators.  
5-6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
6 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
6 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  6 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  
6-7 
  




Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication 
bias, selective reporting within studies).  
6 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), 
if done, indicating which were pre-specified.  
7 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons 
for exclusions at each stage, ideally with a flow diagram.  
8 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations.  
8 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see 
item 12).  
9 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data 
for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
9 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
8-11 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  8-11 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression 
[see Item 16]).  
10-11 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider 
their relevance to key groups (e.g., healthcare providers, users, and policy makers).  
12-15 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
13 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 14-15 
 future research.  
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role 
of funders for the systematic review.  
2 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS 
Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 




Figure 2: MDD prevalence among nursing homes residents. Random-effect sensitivity meta-analysis. Studies were ranked from older 
to most recent indexing. 
 
Note, 9 out of 32 studies were indexed after the year 2010 (roughly, 28% of the sample). 
  
Study name Statistics for each study Event rate and 95% CI Weight (Random)
Event Lower Upper Relative Relative Std Std Std 
rate limit limit Z-Value p-Value weight weight Residual Residual Residual
Hyer L.A. et al., 1984 0.248 0.182 0.328 -5.522 0.000 3.16 0.42
Kay D et al., 1987 0.260 0.204 0.326 -6.418 0.000 3.22 0.50
Parmelee P.A. et al., 1989a 0.106 0.083 0.133 -15.892 0.000 3.26 -0.82
Parmelee P.A. et al., 1989b 0.074 0.057 0.095 -17.871 0.000 3.25 -1.30
Junginger J. et al., 1993 0.210 0.141 0.301 -5.397 0.000 3.07 0.16
Gerety M.B. et al., 1994 0.261 0.194 0.342 -5.287 0.000 3.16 0.50
Burrows A.B. et al., 1995 0.243 0.132 0.405 -2.962 0.003 2.75 0.36
Albrecht Junghans R.E. et al., 1998 0.057 0.032 0.100 -9.038 0.000 2.93 -1.55
Koenig H.G. et al., 1998 0.216 0.183 0.253 -12.355 0.000 3.29 0.21
Laprise R. et al., 1998 0.773 0.657 0.858 4.166 0.000 2.97 3.11
Butler R. et al., 1998 0.060 0.027 0.127 -6.535 0.000 2.65 -1.42
Falck R.P. et al., 1999 0.491 0.365 0.619 -0.132 0.895 3.03 1.67
Goodwin P.E. et al., 1999 0.081 0.072 0.092 -35.827 0.000 3.32 -1.19
Streim J.E. et al., 2000 0.797 0.686 0.876 4.571 0.000 2.95 3.27
Rabins P.V. et al., 2000 0.139 0.110 0.174 -13.323 0.000 3.25 -0.45
Harralson T.L. et al., 2002 0.385 0.321 0.452 -3.298 0.001 3.25 1.20
Anderson R.L. et al., 2003 0.379 0.304 0.461 -2.877 0.004 3.21 1.17
Allgaier A.K. et al. 2004 0.141 0.084 0.228 -6.029 0.000 2.95 -0.40
Damian J. et al., 2004 0.310 0.279 0.343 -10.467 0.000 3.32 0.81
Smalbrugge M. et al., 2005 0.081 0.056 0.116 -12.093 0.000 3.16 -1.16
George K. et al., 2007 0.180 0.141 0.228 -10.090 0.000 3.24 -0.07
Choi N.G. et al., 2008 0.554 0.432 0.669 0.867 0.386 3.06 1.97
Friedman B. et al., 2009 0.135 0.109 0.167 -14.727 0.000 3.27 -0.48
Volicer L. et al., 2011 0.325 0.292 0.360 -9.307 0.000 3.31 0.89
Leontjevas R. et al., 2012 0.139 0.076 0.239 -5.354 0.000 2.86 -0.42
Chu C.L. et al., 2012 0.072 0.041 0.122 -8.539 0.000 2.95 -1.27
Boorsma M. et al., 2012 0.208 0.183 0.237 -15.936 0.000 3.31 0.15
Allgaier A.K. et al., 2013 0.024 0.014 0.040 -13.243 0.000 3.00 -2.63
Tiong W.W. et al., 2013 0.059 0.038 0.090 -11.725 0.000 3.09 -1.56
Lee M.J. et al., 2013 0.121 0.098 0.150 -15.967 0.000 3.27 -0.64
Drageset J. et al., 2013 0.176 0.132 0.231 -8.853 0.000 3.20 -0.10
Van Asch I. F.M. et al., 2013 0.098 0.082 0.118 -21.361 0.000 3.29 -0.93
0.189 0.148 0.238 -9.670 0.000
-0.50 -0.25 0.00 0.25 0.50




Figure n.3: The visual inspection of the funnel plot would exclude a publication bias since most of the original studies were located in 
the top tier of the plot, indicating the larger sampled studies with a lower standard error where overrepresented vs. those with smaller 
sample sizes (bottom of the plot). Notably, the “black diamond” (cumulative effect size) upon trim and fill adjustment substantially 
overlaps with the non-adjusted one (white color). 
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